Compare Bristol-Myers Squibb Co (BMY) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fortinet Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.39 (market cap $116.30B), while Fortinet Inc trades at $163.79 (market cap $122.23B). The key difference: Bristol-Myers Squibb Co and Fortinet Inc are close in size by market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| BMY | FTNT | |
|---|---|---|
Market Cap | $116.30B | $122.23B |
Sector | Health | Technology |
52-Week High | $62.37 | $166.83 |
52-Week Low | $42.60 | $74.39 |
Enterprise Value | $152.24B | $119.43B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Fortinet (FTNT) trades at $160.62, up 1.97% on the day, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.82 exceeding the $0.619 estimate. Revenue growth remains solid, reaching $6.80B in 2025, while high valuation ratios like a P/E of 62.26 reflect premium investor expectations. Recent news highlights expansion in AI-driven security solutions, positioning FTNT to capitalize on rising cybersecurity demand.
The outlook for FTNT is positive, driven by sustained demand for cybersecurity and AI integration, though elevated valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, but the average price target of $121.11 suggests caution relative to the current price. Investors should monitor execution against raised 2026 guidance and industry spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
